Video

know more about us

The prevalence, risks and costs of NASH

What do we know about the lipid effects of PPARs ?

Microvesicles as biomarkers in NAFLD : a clinician’s point of view

Why are we linking PPAR agonists and lipids ?

Liver biopsy in NASH

The risks of NAFLD

The role of liver biopsy in NASH clinical trials

Experimental paper about PPAR’s in the Journal of hepatology

NAFLD : time to update the terminology?

NASH and NAFL: it is not only about liver but it is a complex inter-organ crosstalk in which adipose tissue dysfunction is an important driver of the disease.

Peroxisome prolifrator activated receptors

The role of a global holistic approach in NASH management: important messages

The role of insulin resistance and insulin-sensitizers in NASH management: tips for the practicing clinician

The role of comorbidities in NASH management: a holistic approach

The role of liver sinusoidal endothelial cells

Pre-clinical study with Lanifibranor – Prof Gracia-Sancho

The role of PPARs in NASH fibrogenesis

What can we expect from PPAR agonists in the treatment of NASH?

The role of PPARs in NASH fibrogenesis

The role of PPARs in inflammation

Important trials during the Liver meeting in Boston

Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts

Prof G. Szabo reviews the learnings about alcohol consumption and liver disease that were presented during the Liver meeting 2019 in Boston.

Prof Jean-François Dufour highlights why the Liver meeting 2019 in Boston is relevant for NASH investigators with presentations of new modes of action and non-invasive biomarkers.

Prof Tacke explains why he feels the basic science part of the Liver meeting 2019 in Boston was exciting.

Prof Abdelmalek shares her perspectives about the highlights of the Liver meeting in Boston. She sees a lot of hope in new clinical trials and new biomarkers.

Prof Cusi sheds light on the new exciting information made public at the Liver meeting in Boston

Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.

Prof Dufour discusses best practices about the diagnosis of NASH

Prof Kenneth Cusi, USA discusses the role of diabetologists in screening for NASH

Why are PPAR agonists a promising option for the management of NASH ?

Lipotoxicity in NASH

Prof Szabo, USA discusses the progresses of the quest of biomarkers in NASH

Learn more about the burden of the disease, Prof Sven Francque, Belgium

What are the current definitions ? Prof Abdelmalek, USA

An insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA

Is NASH only about the liver ?